TOMI Environmental Solutions Secures a Purchase Order of Approximately $500,000 for the Integration of SteraMist iHP Technology within a Global Biopharmaceutical Leader

Rhea-AI Summary

TOMI Environmental Solutions (NASDAQ: TOMZ) secured a signed purchase order valued at approximately $500,000 from a global biopharmaceutical leader to integrate the SteraMist iHP technology into passthrough fill boxes used in sterile manufacturing.

The contract covers full integration of the SteraMist Integrated Systems (SIS) platform across two manufacturing areas and includes comprehensive installation and performance qualification (PQ) services to meet regulatory validation requirements. The projects were previously included in a stated $13 million automated-installation pipeline, and TOMI expects further orders through 2026 and beyond.

Positive

• Signed purchase order of approximately $500,000
• Contract includes installation and performance qualification (PQ) services
• SIS deployment across two separate manufacturing areas
• Order listed within a $13 million automated-installation pipeline

Negative

• Current order scope limited to two locations

Key Figures

Purchase order value approximately $500,000 Signed contract for SIS integration with global biopharma leader

Automated projects pipeline $13,000,000 Previously disclosed pipeline for automated installation projects

Custom integration pipeline approximately $3,000,000 Life sciences and medical device customers (Nov 26, 2025 release)

Shelf registration size $50,000,000 Universal S-3 shelf filed Nov 14, 2025

Equity line of credit $20,000,000 Equity Purchase Agreement with Hudson Global Ventures

Q3 2025 revenue $2.01M Q3 2025 results with 95% sequential increase

Q3 2025 gross margin 61% Reported gross margin for Q3 2025

Q3 2025 net loss $450,000 Quarterly net loss, or $(0.02) per share

Market Reality Check

$0.7701 Last Close

Volume Pre-news volume of 7,250 shares is below the 20-day average of 13,780 (relative volume 0.53x). low

Technical Shares at $0.75 were trading below the 200-day MA of $0.90 and about 50% under the 52-week high of $1.50.

Peers on Argus 1 Down

Sector peers showed mixed moves, with LIQT up 1.71% and CLIR, CLWT, DEVS down between 0.83% and 6.88%, while ZONE gained 4.41%, suggesting company-specific drivers for TOMZ rather than a broad sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Product marketing push	Positive	-5.1%	Urged cruise lines to adopt SteraMist for outbreak prevention on ships.
Dec 04	Investor conference	Positive	-0.3%	Announced Sidoti conference presentation and availability for investor meetings.
Nov 26	Pipeline update	Positive	+2.5%	Disclosed ~<b>$3M</b> custom integration pipeline and 10 active projects.
Nov 17	Shelf & ELOC financing	Negative	-8.6%	Filed <b>$50M</b> shelf and <b>$20M</b> equity line, expanding financing flexibility.
Nov 14	Q3 2025 earnings	Negative	-8.6%	Reported Q3 revenue rebound but YTD sales decline and wider operating loss.

Pattern Detected

Recent news often saw negative or muted price reactions, especially around financing and broader marketing updates, while concrete commercial pipeline announcements were better received.

Recent Company History

This announcement adds a concrete ~$500,000 SIS order to TOMI’s recent series of updates highlighting its SteraMist technology. Over the past months, the company reported a 95% sequential revenue increase to $2.01M, a custom integration pipeline of about $3M, and then filed a $50,000,000 S-3 shelf and a $20,000,000 equity line. Those financing steps drew negative reactions, while the pipeline news was better received. Today’s order directly ties into the previously disclosed $13M automated installation pipeline, reinforcing that narrative.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-14

$50,000,000 registered capacity

An effective S-3 shelf filed on Nov 14, 2025 would allow TOMI to offer up to $50,000,000 of various securities over time once effective. As of the latest data, the shelf is not yet effective and shows 0 recorded usages, but it provides flexibility for future capital raises that could impact existing shareholders depending on structure.

Market Pulse Summary

This announcement details a signed purchase contract of approximately $500,000 to integrate the SteraMist SIS platform and iHP technology into critical manufacturing infrastructure at a leading biopharmaceutical company. It converts part of a previously cited $13M automated installation pipeline into booked business, reinforcing demand for automated, validated decontamination solutions. In context of earlier disclosures, including a $50,000,000 S-3 shelf and $20,000,000 equity line, investors may monitor how quickly similar SIS projects close and how future financing is deployed relative to this growing pipeline.

Key Terms

stermist ihp technology medical

"mandates the use of SteraMist iHP technology into passthrough fill boxes"

A Steramist IHP technology is a cleaning system that turns a mild hydrogen peroxide solution into a charged, ultra‑fine mist that spreads evenly and clings to surfaces and hard-to-reach spots to reduce germs and viruses without heavy scrubbing. For investors, it matters because customer demand, safety and regulatory acceptance, and ongoing sales of devices and consumable solutions can create predictable revenue streams and affect a company’s market value, much like a specialized tool businesses buy to prevent costly problems.

performance qualification (pq) technical

"includes comprehensive installation and performance qualification (PQ) services"

Performance qualification (PQ) is the formal testing that proves a manufacturing process or piece of equipment consistently produces products that meet all required specifications under normal operating conditions. Think of it as a road test for a factory line: it confirms the system can reliably deliver the expected result every time. Investors care because a successful PQ reduces regulatory risk, production delays and costly recalls, supporting predictable revenue and valuation.

decontamination medical

"provide a fully automated, rapid, and residue-free decontamination solution"

Decontamination is the process of removing, neutralizing or isolating hazardous substances—such as chemical, biological or radioactive material—from people, equipment, buildings or products so they are safe to use or return to the market. For investors it matters because decontamination can create significant costs, regulatory hurdles, operational downtime and liability risk, much like paying to remove mold or lead before a house can be lived in or sold.

sterility assurance medical

"support their critical manufacturing and sterility assurance needs"

Sterility assurance is the set of validated processes, tests and controls that make and keep a medical product free of live microorganisms, and the measured level of confidence that each unit is sterile. It matters to investors because it affects regulatory approval, manufacturing costs, supply continuity and recall or liability risk — like an effective security system that prevents rare but costly breaches.

throughput requirements technical

"solutions that meet rigorous validation and throughput requirements"

Throughput requirements are the minimum speed or volume a manufacturing line, lab, service process, or computer system must handle to meet demand and regulatory or contractual obligations. Think of it like the number of cars a highway must move per hour: if capacity is too low you get delays, lost sales, higher costs or missed deadlines; if capacity is well matched, the business can grow efficiently and meet market or safety standards. Investors watch these numbers because they indicate potential revenue, margin pressure, and the need for investment to expand or upgrade operations.

validation regulatory

"solutions that meet rigorous validation and throughput requirements"

Validation is the formal process of proving that a test, model, system, or product does what it is intended to do and meets relevant standards or regulations. For investors it matters because validated results reduce uncertainty about performance, safety, or accuracy—making claims and forecasts more trustworthy, lowering regulatory and market risk, and clarifying the likelihood of commercial success. Think of it as an independent check that a promise actually works in the real world.

AI-generated analysis. Not financial advice.

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.^® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today announced it has received a significant signed purchase contract including a purchase order valued at approximately $500,000 from one of the world's largest and most respected biopharmaceutical companies. This order is for the complete integration of TOMI's SteraMist Integrated Systems (SIS) platform into critical manufacturing infrastructure.

The purchase contract specifically mandates the use of SteraMist iHP technology into passthrough fill boxes—a crucial component in the client's sterile manufacturing and advanced therapeutic production process. These systems will be deployed across two separate areas in the global biopharma company specializing in the discovery, development, and manufacture of innovative medicines.

The SteraMist Integrated Systems (SIS) will provide a fully automated, rapid, and residue-free decontamination solution for both critical chambers. The scope of this contract also includes comprehensive installation and performance qualification (PQ) services delivered by TOMI’s expert technical team, ensuring the systems meet stringent biopharmaceutical regulatory requirements for validation.

The SIS platform, formally launched in late 2024, is designed to meet the escalating industry demand for automated, in-line, and high-throughput decontamination. These two projects were previously discussed as part of the $13 million pipeline for automated installation projects, underscoring the SIS platform's effectiveness as it actively drives the pipeline. While the current order focuses on two locations, the increasing industry interest is demonstrated by the robust pipeline of orders anticipated throughout 2026 and beyond.

Elissa (E.J.) Shane, TOMI’s Chief Operating Officer, commented on the milestone: “We value the opportunity to work closely with large pharmaceutical organizations to support their critical manufacturing and sterility assurance needs. We are seeing increasing recognition among large pharmaceutical and biopharmaceutical organizations of the efficacy, material compatibility, and automation advantages of SteraMist iHP technology. In particular, the SteraMist Integrated System platform is generating exceptionally promising interest. As companies evaluate solutions that meet rigorous validation and throughput requirements, the SteraMist Integrated System directly addresses the demand for advanced automation in laboratory and manufacturing chambers.”

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding projected pipeline and potential revenue and sales, timing for completion of SIS projects and expected financial performance in 2026. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com

FAQ

What did TOMI (NASDAQ: TOMZ) announce on December 18, 2025?

TOMI announced a signed purchase order of approximately $500,000 to integrate SteraMist iHP into passthrough fill boxes at a global biopharmaceutical company.

What does the TOMI $500,000 order include for TOMZ shareholders?

The order covers complete SIS integration across two manufacturing areas plus installation and performance qualification (PQ) services.

How does the $500,000 TOMZ order relate to TOMI's pipeline?

The projects were previously part of a stated $13 million automated-installation pipeline and are cited as active drivers of that pipeline.

When was the SteraMist Integrated Systems platform launched?

The SteraMist Integrated Systems platform was formally launched in late 2024.

Will TOMI (TOMZ) provide validation support for the delivered systems?

Yes; the contract explicitly includes installation and performance qualification (PQ) services to meet regulatory validation requirements.